Biologics Brief: E2 Spotlight: Single B-Cell Antibody Discovery: How to Pick the Right Platform for Your Target

Published: June 26, 2026 | Category: Insights, Biologics Discovery

---

Single B-cell discovery is one of the most talked-about modalities in antibody discovery right now. Nearly every platform vendor will tell you their approach is the right answer. The honest truth is that no single platform is best for every campaign, and choosing the wrong one can cost you time, budget, and viable candidates.

In Episode 2, our first Spotlight of The Biologics Brief, Mosaic’s Chief Strategy Officer Tracey Mullen sits down with Christina Palmer, Director of Antibody Discovery and Optimization, to walk through the real differences between these platforms and how to actually decide which one fits your target.

---

What Is Single B-Cell Antibody Discovery, and Why Did It Take Off?

Single B-cell discovery is the direct interrogation of antibody-producing B cells from an immunized animal or donor, without relying on hybridoma fusion or display library construction. The major appeal is that you recover native heavy and light chain pairs from individual B cells, capturing antibodies much closer to how they exist in the immune repertoire.

The modality accelerated dramatically after platforms like the Beacon entered the market, making it possible to interrogate B cells in a controlled, assay-rich environment. Today the category spans optofluidic platforms, FACS-based sorting, microfluidic and microcapillary systems, droplet-based approaches, and sequencing-first workflows.

But single B-cell discovery is not just faster hybridoma or another display format. It is a fundamentally different way of accessing the biology, and the quality of what comes out depends heavily on what happened upstream: the animal model, antigen format, immunization schedule, tissue collected, timing of harvest, and which B cell population you choose to interrogate.

---

Single B-Cell vs. Hybridoma vs. Display: When Each Makes Sense

All three modalities can generate good antibodies. They are just good at different things.

• Single B-cell vs. hybridoma: Single B-cell workflows generally beat hybridoma on speed and diversity, particularly for difficult targets where hybridoma fusion attrition is too costly. The fusion process and outgrowth can bias which B cells you recover; an interesting cell that doesn’t fuse or grow well may never be detected.
• Single B-cell vs. display: Single B-cell wins when native heavy and light chain pairing matters for developability, or when in vivo affinity maturation gives you a meaningful biological head start, particularly for conformational, membrane-associated, or multimeric targets that are difficult to recapitulate in a display system.
• When display still wins: Display remains the stronger answer when you need high-throughput library coverage, want to control selection pressure precisely, or when the target is toxic or highly conserved and immunization is unlikely to generate a useful immune response. You also retain the option to start from a human framework library and avoid humanization entirely.
• When hybridoma still has a role: For familiar, well-characterized, soluble targets where the workflow is proven and downstream infrastructure is already in place, hybridoma remains a reasonable choice.

The right question is not which platform is best, it is what does the target require, what does success look like, and where are the biggest risks in the campaign.

---

The Platform Comparison Vendors Won’t Give You Straight

Once you have decided single B-cell is the right direction, the next decision is which class of platform fits your campaign. Here is an honest breakdown.

• High-content optofluidic platforms (e.g., Beacon): Isolates cells in nanopens and supports sophisticated on-chip assays, secretion, binding, multiplexed blocking, cell-based functional readouts. The strongest platform for difficult targets and complex functional screening where resolution matters more than raw throughput. Not the cheapest or highest throughput option, but if it prevents expressing hundreds of low-value clones or recovers a rare functional hit that a lower-resolution workflow would miss, the value is real.
• FACS-based single B-cell sorting: Fast, accessible, and often relatively inexpensive. Efficient for simple binding campaigns where throughput and speed are priorities. The limitation is lower functional context at the screening step, you are largely sorting on surface binding or antigen alone, with functional triage pushed downstream. Downstream sequencing workflow also determines how well native heavy and light chain pairing is preserved.
• Microfluidic and compartmentalized secretion platforms: These sit in the middle of the spectrum, more assay context than a simple sort, with potentially more flexibility or throughput than high-content optofluidic workflows. The key questions remain the same: what cell population is being screened, what the assay actually measures, how strong the genotype-phenotype linkage is, and what the paired recovery rate looks like.
• Sequencing-first and droplet-based workflows (e.g., 10x Genomics): Massive immune repertoire coverage and paired heavy and light chain sequences at scale. Powerful if your goal is profiling the full repertoire or mining rare events, but generating a large sequence space without functional triage means the discovery burden shifts entirely downstream to expression and validation. You need a strong prioritization strategy before you commit resources to that volume of candidates.

One important note on throughput claims: the realized single-cell throughput of any platform can be a fraction of the theoretical maximum, depending on how cells are loaded. Empty wells, empty droplets, and doublets are statistical realities. The number of physical compartments is not the same as the number of true single cells screened. When evaluating platforms, ask for realized single-cell throughput at the occupancy rate required to preserve clean genotype-phenotype linkage, that is the more meaningful number.

---

How to Actually Pick: Matching Platform to Target

If you are a biotech team trying to choose a single B-cell discovery workflow, start with these questions:

• What is the biology of the target? Is it soluble, membrane-associated, or conformationally complex? Do you need cell binding, blocking, agonism, antagonism, or internalization?
• Which B cell population do you want to interrogate? Plasma cells and plasmablasts are actively secreting, making them attractive for secretion-based screens, but they may represent a different slice of the immune response than memory B cells. Antigen-specific memory B cells can be lower frequency and not actively secreting. Sequencing-first approaches profile broad repertoire diversity but require inference about which sequences matter.
• What does success look like? Maximum repertoire diversity, rare functional binders, epitopic coverage, species cross-reactivity, or a small number of highly validated leads? Each answer points to a different platform.
• Where do you want to place the discovery burden? Pushing triage downstream to recombinant expression makes sense if your organization has the infrastructure to handle it. If downstream capacity is limited, front-loading resolution at the screening stage is the more practical path.
• How do you plan to use AI and computational tools? If you are generating large sequence datasets, you need a prioritization strategy before committing to expression. AI can help rank candidates based on developability, liability risk, sequence diversity, and expression likelihood, but it works best when connected to rich, well-annotated experimental data. Sequence alone is useful. Sequence plus genotype, phenotype, and functional data is significantly more powerful.

The wrong answer from a CRO is “we only have one platform and it is best for everything.”

---

Mosaic’s Point of View: Platform Agnostic, Data Connected

Single B-cell discovery is not one thing, it is a family of workflows. The right workflow depends on the target, the desired antibody profile, which B cell population you want to interrogate, how much functional resolution you need upfront, and how much downstream validation capacity your organization has.

At Mosaic, our approach is platform agnostic and data connected. For some clients, the right answer is broad repertoire capture with AI-guided prioritization feeding into high-throughput recombinant validation. For others, it is lower-throughput but higher-content upfront screening so only the most compelling candidates move downstream. And for others still, the right answer is single B-cell discovery paired with in vitro display, recovering an immune-derived antibody with the right functional profile and then using display-based optimization to improve affinity, developability, or format.

We start with the target, define the campaign goal, understand the biology, understand the organization’s bottlenecks, and then build a workflow around that. That is the conversation worth having before you commit.

---

---

View and listen to the full video conversation on The Biologics Brief.

---